DANAHER CORP /DE/
NYSE: DHR·Washington, District of Columbia·CIK 0000313616
- Price
- $229.91
- Base IV
- $56.06
Valuation snapshot
At $229.91, the price is above even our bull case of $93.17.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $56.06
- 24% of the price · range $23.23–$93.17
- Price vs base case
- 310% above
- $229.91 against $56.06
- Base case · our researched forecast, 2026-10-27See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $23.23 to bull $93.17. Values per share.
Price against each value
- Bear case
- $23.23
- Price 890% above
- No growth
- …
- —
- Base case
- $56.06
- Price 310% above
What does Danaher Corp /de/ do?
Danaher provides equipment, consumables, and services to help biopharmaceutical and diagnostic companies develop, manufacture, and test biological medicines and medical therapies.
It brought in $25.6B of sales in the 12 months to Sep 2026.
Led by Julie Sawyer Montgomery, President and Chief Executive Officer since 2026. Danaher Corp Form 8-K Current Report (Item 5.02)
- Industry
- Semiconductors
- Based in
- Washington, District of Columbia
- Trades on
- NYSE as DHR
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 17¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 41¢ of every dollar.
- Making what it sells41¢
- Research and development7¢
- Sales, marketing and admin32¢
- Interest and other costs2¢
- Tax2¢
- Left as profit17¢
Who pays Danaher Corp /de/, and for what?
Danaher makes scientific instruments, lab supplies, software and services that are used to develop medicines, run research and test patients for disease. Much of its revenue comes from repeat sales of supplies and services that customers use with equipment Danaher has already sold them. It reports three segments: Biotechnology, Life Sciences and Diagnostics.
Mostly businesses and institutions: drug and biotech companies, contract manufacturers, universities and research labs, hospitals, testing laboratories and doctors' offices, with about 59% of 2025 sales from outside the U.S.
Biotechnology
30%Equipment and single-use supplies that drug makers use to develop and manufacture biologic medicines, under brands such as Cytiva and Pall.
Cytiva ÄKTA ready single-use chromatography systemImage: SelectScience Life Sciences
30%Research instruments such as mass spectrometers, microscopes and cell-analysis machines, plus lab supplies like antibodies and custom DNA, under brands such as SCIEX and IDT.
Leica STELLARIS confocal microscopeImage: Leica Microsystems Diagnostics
41%Testing systems and supplies for hospital labs, molecular testing (including respiratory tests), emergency care and pathology, under brands such as Beckman Coulter and Cepheid. Masimo joined this segment in June 2026.
Cepheid GeneXpert molecular diagnostic systemAliva Sahoo, CC BY-SA 4.0, via Wikimedia Commons
Where its work physically happens, beyond headquarters:
- Cytiva Uppsala chromatography-resin site — Uppsala, Sweden. This 160,000-square-meter site is one of the world's largest chromatography-media manufacturing operations, producing resins that are critical consumables for purifying biologic medicines.
- Aldevron Breakthrough Campus — Fargo, United States. The 265,000-square-foot campus is one of the world's largest cGMP plasmid-DNA manufacturing facilities and contains 32 cGMP production suites for DNA, mRNA drug substance and drug product, and proteins.
- Cytiva Logan cell-culture media campus — Logan, United States. Cytiva's cell-culture center of excellence manufactures liquid and powdered media, process liquids, and serum, with a recent expansion adding manufacturing suites and doubling site capacity.
- IDT Coralville manufacturing campus — Coralville, United States. The expanded campus provides more than three times its prior synthesis capacity for customizable oligonucleotides used in minimal-residual-disease and next-generation-sequencing oncology workflows.
- Pall Singapore semiconductor-filtration facility — Singapore, Singapore. This approximately $150 million, 18,000-square-meter high-volume facility manufactures advanced filtration products for leading-edge logic and memory semiconductor fabrication.
How is the business doing?
Sales grew from $22.3B in 2020 to $24.6B in 2025, about 2% a year.
Running the business leaves about 20¢ of each sales dollar as operating profit, about the same as 19¢ in 2020.
After paying for its upkeep and new investment, it had $5.7B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Danaher says it exists to use science and technology to improve people's health.
“committed to accelerating the power of science and technology to improve human health”
Who is responsible for the plan?
- Julie Sawyer MontgomeryPresident and Chief Executive Officer
Oversees Danaher's overall corporate strategy, global business operations, and operating companies across Biotechnology, Life Sciences, and Diagnostics. Danaher generates revenue through the development, manufacture, and commercialization of medical, diagnostic, and life sciences products and consumables.
- Chris RileyExecutive Vice President, Biotechnology Group
Oversees Danaher's Biotechnology platform and the operations of Cytiva and its associated bioprocessing businesses. The Biotechnology segment generates revenue by providing technologies, consumables, and services used in the development and manufacture of biopharmaceuticals.
- Jose-Carlos Gutierrez-RamosSenior Vice President and Chief Science Officer
Oversees Danaher's enterprise-wide science and technology strategy, open innovation initiatives, the Danaher Innovation Centers, and the Scientific Advisory Board. This scientific strategy guides technological capabilities and innovation across Danaher's operating companies developing diagnostic instruments and life sciences workflows.
Roles checked November 14, 2026.
What management says it is working on now:
Bringing Masimo into the company
Danaher completed its purchase of Masimo, a maker of patient-monitoring devices, on June 10, 2026 for about $9.8 billion in cash. Masimo had about $1.5 billion in 2025 sales and is now part of the Diagnostics segment.
Danaher Corporation Form 10-Q for quarter ended June 26, 2026Getting growth back up
Management said it expects to end 2026 growing sales at a mid-single-digit rate before acquisitions, helped by recovering customer demand and its own growth efforts.
Danaher Reports Second Quarter 2026 ResultsRunning the business through the Danaher Business System
The company says it builds its edge by using its own set of continuous-improvement methods across every business. These cover growth, efficiency and leadership.
Danaher Corporation Form 10-K for fiscal year 2025Reshaping the portfolio through acquisitions
Danaher puts money into buying businesses in science and health markets it finds attractive. After Masimo, it agreed to buy StatLab, a pathology lab supplies company with about $250 million in 2025 revenue.
Danaher Reports Second Quarter 2026 ResultsLeadership handover
Julie Sawyer Montgomery, who previously ran the Diagnostics business, became President and CEO on October 1, 2026. Rainer Blair, CEO since 2020, retired and stays on as an adviser until March 31, 2027.
Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
- Core revenue growth (excludes acquisitions and currency effects), full year 2026
- 3% to 4%
- Danaher Reports Second Quarter 2026 Results
- Core revenue growth (excludes acquisitions and currency effects), third quarter 2026
- 2% to 3%
- Danaher Reports Second Quarter 2026 Results
- Adjusted earnings per share, full year 2026
- $8.45 to $8.60
- Danaher Reports Second Quarter 2026 Results
- Core revenue growth rate at year end, exiting 2026
- Mid-single digits
- Danaher Reports Second Quarter 2026 Results
- StatLab long-term core sales growth, long term
- High-single digits
- Danaher Reports Second Quarter 2026 Results
What's changing right now?
Growth is picking up. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 5%.
Its operating margin is about where it was a year ago, 19¢ per sales dollar.
Since Sep 2026 the share price has risen 9%, from $211.03 to $229.91.
Recently
September 25, 2026
Quarterly core sales growth excluding respiratory testing changed to 5.5%
Danaher Q3 2026 ResultsSeptember 25, 2026
Capital additions to sales, first nine months changed to 4.0%
Danaher Q3 2026 Form 10-QSeptember 25, 2026
GAAP operating margin, third quarter changed to 19.0%
Danaher Q3 2026 Form 10-Q
Coming up
2026-10-21
Third-quarter 2026 results
Danaher plans to report third-quarter results and hold a call with investors. These will show whether sales growth is landing in its 2% to 3% forecast for the quarter.
Danaher Reports Second Quarter 2026 ResultsBy end of 2026
StatLab acquisition closing
Danaher expects to finish buying StatLab, a pathology lab supplies maker with about $250 million in 2025 revenue. It says the deal will add to earnings per share in the first full year.
Danaher Reports Second Quarter 2026 ResultsOctober 2026 to March 2027
New CEO's first months
Julie Sawyer Montgomery took over as CEO on October 1, 2026, and Rainer Blair stays on as an adviser until March 31, 2027. The company said the change did not alter its 2026 forecasts.
Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
Our own estimate moved too: the base case went from $51.84 to $56.06 a share between our last two valuations. The biggest reason: Capital additions to sales, first nine months moved from an unreported prior value to 4.0%, as reported in Danaher Q3 2026 Form 10-Q.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
China price pressure and policy
About 11% of 2025 sales came from China. There, government programs that buy medical products in bulk to push prices down have already hurt revenue, and policy and economic uncertainty remain.
From the company's own filingsWould hit how fast sales growDanaher Corporation Form 10-K for fiscal year 2025
Cuts to research and biotech funding
Government research budgets have been reduced, and money for young biotech companies has been tighter. That has lowered demand for some of Danaher's research tools and could keep doing so.
From the company's own filingsWould hit how fast sales growDanaher Corporation Form 10-K for fiscal year 2025
Higher debt after the Masimo deal
Long-term debt rose to about $25.1 billion in mid-2026 from $18.4 billion at the end of 2025, mainly to pay for Masimo. More debt means higher interest costs and less room for other spending if business weakens.
From the company's own filingsWould hit how much it has to reinvestDanaher Corporation Form 10-Q for quarter ended June 26, 2026
Combining acquired businesses
Danaher relies on buying companies. It may struggle to blend them in or get the expected benefits, and Masimo's costs already lowered Diagnostics profit in the second quarter of 2026.
From the company's own filingsWould hit how much of each sale it keepsDanaher Corporation Form 10-Q for quarter ended June 26, 2026
Tariffs and trade rules
Changing tariffs and trade restrictions can raise the cost of parts and products or make them harder to get. That could squeeze profits, especially with most sales coming from outside the U.S.
From the company's own filingsWould hit how much of each sale it keepsDanaher Corporation Form 10-K for fiscal year 2025
Uneven demand for respiratory tests and drug-making supplies
Sales of respiratory tests rise and fall with how bad flu and COVID seasons are. Bioprocessing sales also depend on when customers' projects happen, and that timing dragged on second-quarter 2026 revenue.
From the company's own filingsWould hit how fast sales growDanaher Reports Second Quarter 2026 Results
Total core sales growth was only 0.03 in Q3 and management expects about 0.025 for full-year 2026.
From our researchWould hit how fast sales growDanaher Q3 2026 results
The filing identifies continuing dilution from acquired businesses and added amortization following Masimo.
From our researchWould hit how much of each sale it keepsDanaher Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2025 it earned between 6% and 11% on the capital invested in it, a median of 7%. Its cost of capital in the latest valuation is 8.1%; returns were above it in 3 of the 10 years.
From 2016 to 2025 it earned between 7% and 14% on its shareholders' equity, a median of 9%.
Over 10 years its operating margin ranged from 16¢ to 28¢ per sales dollar, a median of 19¢. Gross margin ran from 55¢ to 61¢.
Cost of capital 8.1%
The number of shares has held roughly steady over the past year.
It owes $20.8B more than it holds in cash, about 4.0 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $229.91. Our put its value between $23.23 and $93.17, with $56.06 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $23.23
Despite faster sales in the latest quarter, demand softens, costs stay elevated, and Danaher earns less from the money it puts back into the business.
Base case, $56.06
After sales improved through 2026, Danaher keeps growing at a steady pace, and profits recover somewhat as its recent purchase settles in.
Bull case, $93.17
The recent pickup in sales continues, Masimo adds lasting growth, and Danaher turns more of each sale into profit.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 310%
For Danaher Corp /de/ to be worth today's $229.91, sales would need to grow about 32.7% a year. We assume 4.5%. Over the last 5 years, sales shrank 1.8% a year.
Or, if sales grow 4.5% as we assume, the price works with a profit margin of 62.2% (we assume 20.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 32.7% a year?
Try your own numbersWe're moderately sure of this range: it scores 53 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $56.06 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.5%
- Operating margin20.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$56.06 -75.6%

